 |
 |
Oxford BioMedica is currently recruiting for clinical trials as detailed below. If you are interested in future clinical trials for any of Oxford BioMedica’s products, please email your contact details to [log in to unmask] ProSavin® A Phase I/II study of the safety, efficacy and dose evaluation of ProSavin®, administered using stereotactic injection to the striatum of patients with bilateral, idiopathic Parkinson’s disease. EudraCT Number: 2007-001109-26 Principal Investigator: Professor Stéphane Palfi Neurosurgery Department, Henri Mondor Hospital, Créteil, France Tel: +33 (0) 149812203 Fax: +33 (0) 149812202 Principal Investigator: Dr. Roger Barker Cambridge Centre for Brain Repair Forvie Site, Robinson Way, Cambridge CB2 0PY Tel: +44 (0) 1223 331160 Fax: + 44 (0) 1223 331174 FYI - They are currently recruiting... Been watching this for 2 years now. Really hopeful! -----Original Message----- From: Rayilyn Brown <[log in to unmask]> To: PARKINSN <[log in to unmask]> Sent: Fri, Apr 13, 2012 1:01 am Subject: IS THIS IT??? http://www.foxnews.com/health/2012/04/12/scientists-develop-groundbreaking-treatment-for-parkinson-disease/ Ray ayilyn Brown ast Director AZNPF rizona Chapter National Parkinson Foundation ---------------------------------------------------------------------- o sign-off Parkinsn send a message to: mailto:[log in to unmask] n the body of the message put: signoff parkinsn ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn